Genaera to Release / Webcast First Quarter 2001 Financial Results On Tuesday, May 1, 2001

Apr 27, 2001, 01:00 ET from Genaera Corporation

    PLYMOUTH MEETING, Pa., April 27 /PRNewswire/ -- Genaera Corporation
 (Nasdaq:   GENR) today announced that its first quarter 2001 financial results
 will be released on Tuesday, May 1, at 7:00 a.m. Eastern Standard Time (EDT).
     At 4:30 p.m. EDT, as part of the Company's efforts to ensure full
 disclosure, Genaera will webcast a conference call hosted by Roy C. Levitt,
 MD, President and Chief Executive Officer.
     Those who wish to participate in the conference call may telephone
 (888) 313-7820 approximately 15 minutes before the start time
 (Conference ID: 18513138).  A replay will be available by telephone until
 May 3, 2001 at (800) 633-8284 toll free in the United States or (858) 812-6440
 for international callers.
     To access the live call or the 7-day archive via the Internet, please log
 onto http://www.vcall.com/NASApp/VCall/EventPage?ID=71949.  Please connect to
 the site prior to the conference call to ensure adequate time for any software
 download that may be needed to hear the webcast.
 
     Genaera Corporation, formerly Magainin Pharmaceuticals Inc., is a
 biopharmaceutical company committed to developing medicines for serious
 diseases from genomics and natural products.  Research and development efforts
 are focused on anti-angiogenesis, obesity, infectious and respiratory
 diseases.
 
     This announcement contains forward-looking statements that are subject to
 risks and uncertainties.  Forward-looking statements reflect management's
 current views and are based on certain expectations and assumptions.  Such
 statements, among others, reflect management's current views and are based on
 certain assumptions.  Genaera's actual results and performance could differ
 materially from those currently anticipated and expressed in these and other
 forward-looking statements as a result of a number of factors, including, but
 not limited to, the additional data to be collected from the clinical trials,
 results of additional clinical development plans, results of ongoing
 preclinical and clinical studies in our drug development candidates, general
 financial, economic, regulatory and political conditions affecting the
 biotechnology industry and the other risks and uncertainties discussed in this
 announcement and in Genaera's filings with the Securities and Exchange
 Commission.  Genaera does not intend (and it is not obligated) to publicly
 update, revise or correct these forward-looking statements.   This discussion
 is permitted by the Private Securities Litigation Reform Act of 1995.
 
                     MAKE YOUR OPINION COUNT -- Click Here
                http://tbutton.prnewswire.com/prn/11690X63857488
 
 

SOURCE Genaera Corporation
    PLYMOUTH MEETING, Pa., April 27 /PRNewswire/ -- Genaera Corporation
 (Nasdaq:   GENR) today announced that its first quarter 2001 financial results
 will be released on Tuesday, May 1, at 7:00 a.m. Eastern Standard Time (EDT).
     At 4:30 p.m. EDT, as part of the Company's efforts to ensure full
 disclosure, Genaera will webcast a conference call hosted by Roy C. Levitt,
 MD, President and Chief Executive Officer.
     Those who wish to participate in the conference call may telephone
 (888) 313-7820 approximately 15 minutes before the start time
 (Conference ID: 18513138).  A replay will be available by telephone until
 May 3, 2001 at (800) 633-8284 toll free in the United States or (858) 812-6440
 for international callers.
     To access the live call or the 7-day archive via the Internet, please log
 onto http://www.vcall.com/NASApp/VCall/EventPage?ID=71949.  Please connect to
 the site prior to the conference call to ensure adequate time for any software
 download that may be needed to hear the webcast.
 
     Genaera Corporation, formerly Magainin Pharmaceuticals Inc., is a
 biopharmaceutical company committed to developing medicines for serious
 diseases from genomics and natural products.  Research and development efforts
 are focused on anti-angiogenesis, obesity, infectious and respiratory
 diseases.
 
     This announcement contains forward-looking statements that are subject to
 risks and uncertainties.  Forward-looking statements reflect management's
 current views and are based on certain expectations and assumptions.  Such
 statements, among others, reflect management's current views and are based on
 certain assumptions.  Genaera's actual results and performance could differ
 materially from those currently anticipated and expressed in these and other
 forward-looking statements as a result of a number of factors, including, but
 not limited to, the additional data to be collected from the clinical trials,
 results of additional clinical development plans, results of ongoing
 preclinical and clinical studies in our drug development candidates, general
 financial, economic, regulatory and political conditions affecting the
 biotechnology industry and the other risks and uncertainties discussed in this
 announcement and in Genaera's filings with the Securities and Exchange
 Commission.  Genaera does not intend (and it is not obligated) to publicly
 update, revise or correct these forward-looking statements.   This discussion
 is permitted by the Private Securities Litigation Reform Act of 1995.
 
                     MAKE YOUR OPINION COUNT -- Click Here
                http://tbutton.prnewswire.com/prn/11690X63857488
 
 SOURCE  Genaera Corporation